SOURCE: Amarin Corp. Plc

Amarin Corp. Plc

September 03, 2014 07:00 ET

Amarin to Present at the Rodman & Renshaw 2014 Global Investment Conference

BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 03, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Rodman & Renshaw 2014 Global Investment Conference on Wednesday, September 10, 2014, at 2:05 p.m. ET.

A live audio webcast of the presentation will be available at:

http://wsw.com/webcast/rrshq24/amrn

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is an ultra-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Contact Information